Bemarituzumab + Flot regimen
ICO-2023-10
Phase 2 small_molecule terminated
Quick answer
Bemarituzumab + Flot regimen for Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- UNITED THERAPEUTICS Corp
- Indication
- Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated